• By November 2020, the WHO said, "Do not use Remdesivir."

• But instead, HHS added a 20% bonus on the entire hospital if they administered this liver and kidney-toxic drug.

Science has learned that both FDA's decision and the EU deal came about under unusual circumstances that gave the company important advantages. FDA never consulted a group of outside experts that it has at the ready to weigh in on complicated antiviral drug issues.

The European Union, meanwhile, decided to settle on the remdesivir pricing exactly 1 week before the disappointing Solidarity trial results came out. It was unaware of those results, although Gilead, having donated remdesivir to the trial, was informed of the data on 23 September and knew the trial was a bust.

"This is a very, very bad look for the FDA, and the dealings between Gilead and EU make it another layer of badness," says Eric Topol, a cardiologist at the Scripps Research Translational Institute who objected to remdesivir's FDA approval.

https://www.science.org/content/article/very-very-bad-look-remdesivir-first-fda-approved-covid-19-drug